Wyss InstituteCell Biology – Wyss Institute

Recapitulating intramuscular vaccination with mRNA vaccines in patient-specific Lymphoid Organ Chips

Mariel Schoen — Fri, 17 Jul 2026 13:55:40 +0000

By Benjamin Boettner (BOSTON) — The protective abilities of the Moderna and BioNTech mRNA vaccines developed against COVID-19 saved millions of lives during the pandemic and put this platform technology in the spotlight of vaccine research. By now, mRNA vaccines for other infectious diseases, such as influenza, RSV, and HIV are being tested in clinical trials and highly anticipated.

Source

TIB: Tolerance Inducing Biomaterials for Regulatory T Cells

Jessica Leff — Mon, 06 Jul 2026 17:38:18 +0000

Tissue regeneration following injuries and degenerative processes benefits greatly from the activity of regulatory T cells (Tregs) that help balance the immune system, which senses, regulates, and helps restore tissue environments following injury and in disease. In fact, immune therapies using Tregs have shown first promise in treating a wider variety of diseases. However…

Source

David Chou on keeping people safe from radiation on Earth and beyond

Jessica Leff — Thu, 28 May 2026 13:00:27 +0000

The Humans of the Wyss (HOW) series features members of the Wyss community discussing their work, the influences that shape them as professionals, and their collaborations at the Wyss Institute and beyond. David Chou’s work is literally out of this world! In addition to identifying radiation countermeasures for use on Earth, he is part of the AVATAR project, which aims to understand how humans…

Source

Decoding inflammatory bowel disease – on a chip

Jessica Leff — Thu, 21 May 2026 09:30:43 +0000

By Benjamin Boettner (BOSTON) — Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn’s disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated. This is mostly due to a lack of understanding of what exactly causes the increased inflammation, fibrosis, and compromised intestinal barrier that underlie this…

Source

Materializing safe, on-demand living therapeutics

Jessica Leff — Thu, 14 May 2026 17:55:55 +0000

By Benjamin Boettner (BOSTON) — Patient recovery from many debilitating conditions and diseases could be sped up significantly and be more effective if drugs and therapeutic molecules were delivered right to where they are needed in the body, over the entire regenerative process, and in doses finely tuned to therapeutic needs. An intriguing way to achieve this is the use of implantable…

Source

Growing liver tissue on demand directly in the body

Jessica Leff — Fri, 17 Apr 2026 17:55:10 +0000

By Benjamin Boettner (BOSTON) — In patients developing end-stage liver disease, the damage has become too severe for the liver’s normally extraordinary regenerative capacity to repair or compensate for it. Once this “point of no return” has been reached, the only option is an organ transplant. However, getting a liver transplant is extremely difficult due to high demand and limited supply…

Source

Wyss Institute technologies enable breakthrough in astronaut health research aboard NASA’s Artemis II mission

Jessica Leff — Thu, 09 Apr 2026 14:55:20 +0000

By Alexandra Jirstrand (BOSTON) – Launched on April 1, 2026, Artemis II is a historic, approximately 10-day lunar flyby mission that is sending four astronauts farther into space than any humans have traveled since the Apollo era, marking a critical step toward sustained lunar exploration and future missions to Mars. The Wyss Institute for Biologically Inspired Engineering at Harvard…

Source

Toward autonomous self-organizing biological robots with a nervous system

Mariel Schoen — Mon, 16 Mar 2026 18:30:42 +0000

By Benjamin Boettner (BOSTON) — Biobots, whose growing line of variants started with Xenobots, are fascinating tiny self-powered living robots built exclusively using frog embryonic cells. Originally developed in the laboratories of Wyss Institute Associate Faculty member and Tufts University Professor Michael Levin, Ph.D. and his collaborators at University of Vermont…

Source

Nucleic Acid Delivery Consortium

Mariel Schoen — Fri, 13 Mar 2026 15:13:09 +0000

Nucleic acid therapies are emerging as a revolutionary class of medicines. Using engineered DNA or RNA molecules, they treat diseases at their genetic source, thus offering potential cures for a large variety of disorders, ranging from genetic disorders to cancers and infectious diseases. Different technologies, including mRNA, short interfering RNAs (siRNA), antisense oligonucleotides (ASOs)…

Source

Building protection against infectious diseases with nanostructured vaccines

Mariel Schoen — Wed, 11 Mar 2026 12:56:44 +0000

By Benjamin Boettner (BOSTON) — The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December 2020 and mathematical models suggest that mRNA vaccines prevented at least 14.4 million deaths from COVID-19 in the first year alone.

Source